English High Court upholds Copaxone patent

The ruling is a major setback for Mylan's efforts to market a generic version of Teva's multiple sclerosis treatment before 2015.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today announced that the High Court for England and Wales has ruled in Teva's favor in the patent litigation case it brought against Mylan Inc. (NYSE: MYL) subsidiary Generics (UK) Ltd. to protect Teva's multiple sclerosis treatment, Copaxone. The High Court found that Teva's European patent for Copaxone was valid through May 23, 2015.

Today's ruling is another major setback for Mylan and its efforts to produce and market a generic version of Copaxone before 2015.

Generics (UK) had sought to obtain a declaration that its proposed generic version of Copaxone would not infringe the drug's European patent and to revoke the patent's expiration date. The High Court ruled in Teva's favor on both counts.

The English High Court's ruling comes less than three weeks after a similar ruling in the US. On June 23, the US District Court for the Southern District of New York ruled in Teva's favor in its patent infringement lawsuit against Momenta Pharmaceuticals Inc. (Nasdaq: MNTA)/Sandoz Inc. and Mylan/Natco Pharmaceuticals Ltd. (BSE: 524816) over Copaxone. The court ruled that Teva's US Copaxone patents are valid. The last of these patents expires on September 1, 2015. The judge ruled against Momenta/Sandoz and Mylan/Natco’s claims that the Copaxone patents were invalid and unenforceable, and found that the purported generic versions of the drug for which Momenta/Sandoz and Mylan/Natco seek Food and Drug Administration (FDA) approval infringed those patents.

Teva's share price rose 0.9% by early afternoon on the TASE, following the announcement, to NIS 156.90, after rising 0.1% on the New York Stock Exchange yesterday to $39.29, giving a market cap of $34.2 billion.

Published by Globes [online], Israel business news - www.globes-online.com - on July 11, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Erez Vigodman Teva boosted by European drug recommendations

Teva's share jumped 4% in Tel Aviv, after climbing 4.9% on Wall Street.

Partner/Orange Partner launches smartphone medical services

The new services includes prescriptions, hospital referrals, and confirmation of illness.

Reuven Krupik Clal Biotech unit PolyHeal nears licensing deal

PolyHeal has signed an MOU with a European drug company for an exclusive global license.

Nasdaq Galmed jumps on FDA hepatitis drug approval

The FDA awarded Fast Track Designation to aramchol for the treatment of Non-Alcoholic Steato-Hepatitis.

artificial sweeteners Weizmann Inst: Sweeteners cause diabetes, obesity

A study found that artificial sweeteners adversely affect intestinal bacteria.

BioCancell share jumps on positive cancer trial results

The clinical trials demonstrated safety and effectiveness of the treatment on high-risk bladder cancer patients.

Trendlines Group set for Toronto IPO

The technological incubators company is raising C$9 at a company value of C$80 million, after money.

Reuven Krupik Clal Biotech sues Hyperion for $200m

Clal Biotechnology alleges Hyperion made "rash and ill-considered" decisions in the Andromeda affair.

pharmaceuticals Clal Biotech: No evidence of misconduct by us

Clal Biotech says documents it was shown by Hyperion do not indicate it committed any misconduct regarding Andromeda.

Soroka Hospital  picture: Eyal Yitzhar Visiting Israel’s wounded at Soroka

Soroka Medical Center in Beersheva, the Israeli hospital closest to Gaza, bears the medical brunt of Operation Protective Edge.

Twitter Facebook Linkedin RSS Newsletters גלובס